Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients
Open Access
- 23 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 4 (3) , pkaa032
Abstract
Cisplatin-based chemotherapy may induce nephrotoxicity. This study presents a random forest predictive model that identifies testicular cancer patients at risk of nephrotoxicity before treatment. Clinical data and DNA from saliva samples were collected for 433 patients. These were genotyped on Illumina HumanOmniExpressExome-8 v1.2 (964 193 markers). Clinical and genomics-based random forest models generated a risk score for each individual to develop nephrotoxicity defined as a 20% drop in isotopic glomerular filtration rate during chemotherapy. The area under the receiver operating characteristic curve was the primary measure to evaluate models. Sensitivity, specificity, and positive and negative predictive values were used to discuss model clinical utility. Of 433 patients assessed in this study, 26.8% developed nephrotoxicity after bleomycin-etoposide-cisplatin treatment. Genomic markers found to be associated with nephrotoxicity were located at NAT1, NAT2, and the intergenic region of CNTN6 and CNTN4. These, in addition to previously associated markers located at ERCC1, ERCC2, and SLC22A2, were found to improve predictions in a clinical feature–trained random forest model. Using only clinical data for training the model, an area under the receiver operating characteristic curve of 0.635 (95% confidence interval [CI] = 0.629 to 0.640) was obtained. Retraining the classifier by adding genomics markers increased performance to 0.731 (95% CI = 0.726 to 0.736) and 0.692 (95% CI = 0.688 to 0.696) on the holdout set. A clinical and genomics-based machine learning algorithm improved the ability to identify patients at risk of nephrotoxicity compared with using clinical variables alone. Novel genetics associations with cisplatin-induced nephrotoxicity were found for NAT1, NAT2, CNTN6, and CNTN4 that require replication in larger studies before application to clinical practice.Keywords
Funding Information
- Idella Foundation
- Sino-Danish Center
This publication has 47 references indexed in Scilit:
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective InterventionsThe American Journal of Pathology, 2010
- Cellular Responses to Cisplatin‐Induced DNA DamageJournal of Nucleic Acids, 2010
- DNA Damage, Mutagenesis, and DNA RepairJournal of Nucleic Acids, 2010
- Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsThe Pharmacogenomics Journal, 2009
- Interaction of Cisplatin with the Human Organic Cation Transporter 2Clinical Cancer Research, 2008
- Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of InhibitionMolecular Pharmacology, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cellsKidney International, 1995